Mutant BCL6 will abnormally situate near genes that trigger apoptosis ... a Professor at Stanford. This method aims to turn on a pathway that is normally off, instead of inhibiting something that ...

Scientists working in a lab. Image source: chokniti / Adobe One of the main proteins used in the new procedure is called BCL6, and when it mutates, it actually drives blood cancer. Medical ...

Sarott et al. set out to repurpose these CDK inhibitors as chemical inducers of proximity (CIPs) that activate genes repressed by the DNA-binding transcription factor BCL6. This oncoprotein ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health ...

Quebec has hit the breaks on two major permanent resident pathways. Effective immediately, Quebec is no longer accepting applications for the Quebec Experience Program - Quebec Graduates (PEQ - ...

1Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China. 4School of Pharmaceutical Sciences and ...

Contrary to the belief that the path to sustainable development is increasingly out of reach, the results show that humankind has a variety of pathways to depart from its current unsustainable ...

We are also encouraged by the preclinical profile of ARV-393, our BCL6 PROTAC degrader currently being evaluated in a first-in-human Phase 1 clinical trial in patients with B-cell lymphomas.